Human trials target superbugs

March 6, 2018, The Lead
Dr Katharina Richter examines a golden staph sample as part of her research into defeating superbugs. Credit: Russell Millard/University of Adelaide

The first human trials of a new approach to fight superbugs by starving them of iron are underway in South Australia.

Superbugs, or such as , cannot be killed by existing methods and cause 700,000 deaths globally every year.

The threat from superbugs to human health is likely to worsen, with the World Health Organization predicting 10 million people will die each year due to antibiotic resistance by 2050.

Dr. Katharina Richter and colleagues from the University of Adelaide have developed and patented a novel approach to fight superbugs by targeting the bugs' favourite food – iron.

The South Australian researchers targeted how bacteria consume iron to make them vulnerable and ultimately kill them.

"Iron is like chocolate for bacteria. It gives them energy to grow, cause disease, and withstand attacks from our immune systems and antibiotics," said Dr. Richter.

"Using two different compounds, we first starve the bacteria of iron and then feed them the bacterial equivalent of poisonous chocolate, which the hungry bacteria find irresistible.

"This 'double whammy' approach has defeated superbugs like golden staph in laboratory and animal studies."

The treatment is being trialled at The Queen Elizabeth Hospital in Adelaide to help patients with antibiotic-resistant sinus infections – with the two compounds included in a wound-healing gel.

"The treatment is locally applied at the site, precisely where it is needed without interfering with the entire body," Dr. Richter said.

Dr. Richter said a key benefit of the treatment is that the risk for resistance is low because bacteria are unlikely to become resistant to their preferred food.

The team is recruiting patients with chronic recurring sinus infections for the trials and hopes the therapy can be refined so it can also be used to treat other infections.

Ear, nose and throat surgeon at The Queen Elizabeth Hospital and chair of Otolaryngology, Head and Neck Surgery at the University of Adelaide Professor Peter-John Wormald said he hoped the treatment would improve the quality of life for patients after

"By better treating the causing their infections we hope to extend the period of time patients are symptom-free, and potentially reduce their need for further surgery."

Explore further: Promising new treatment joins the war on superbugs

Related Stories

Promising new treatment joins the war on superbugs

December 1, 2015
The fight against superbugs has been bolstered thanks to a promising new therapy discovered by University of Adelaide researchers.

Supercharged antibiotics could turn tide against superbugs

January 5, 2018
An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world's most dangerous superbugs.

Key to 'superbug' antibiotic resistance discovered

May 16, 2017
An international study led by Monash University has discovered the molecular mechanism by which the potentially deadly superbug 'Golden Staph' evades antibiotic treatment, providing the first important clues on how to counter ...

Most staph infections resistant to antibiotics occur in the community

October 30, 2017
The proportion of staph infections resistant to antibiotics has increased in Australia since 2000 with most cases now occurring in the community rather than in hospitals, a new study led by ANU has found.

Recommended for you

Small-scale poultry farming could mean big problem in developing countries

December 16, 2018
Small-scale farming in developing countries provides those in rural communities with income and access to protein, but it may have a large impact on antibiotic resistance, according to a new University of Michigan study.

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.